SUPPLEMENT

Q2 2025 — Other Financial Disclosures

Q2 2025PDF · 17 pages583 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 7
Table 4: Condensed Consolidated Statement of Earnings - QTD 8
Table 5: Condensed Consolidated Statement of Earnings - YTD 9
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 10
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 11
Table 8: Non-GAAP Adjusted Net Earnings 12
Table 9: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 13
Table 10: Non-GAAP P&L by Segment Reconciliation 2024 - QTD 14
Table 11: Non-GAAP P&L by Segment Reconciliation 2025 - YTD 15
Table 12: Non-GAAP P&L by Segment Reconciliation 2024 - YTD 16
Second Quarter 2025
Other Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 2024 Total Operations Currency 2025 2024 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 9,161	$ 8,510 7.6 % 7.6 - 17,253	$ 16,122 7.0 % 7.0 -
International 6,041 5,980 1.0 (1.6) 2.6 11,822 11,930 (0.9) (0.1) (0.8)
15,202 14,490 4.9 3.8 1.1 29,075 28,052 3.6 4.0 (0.4)
MedTech
U.S. 4,383 4,059 8.0 8.0 - 8,596 8,067 6.6 6.6 -
International 4,158 3,898 6.7 4.1 2.6 7,965 7,711 3.3 3.6 (0.3)
8,541 7,957 7.3 6.1 1.2 16,561 15,778 5.0 5.1 (0.1)
U.S. 13,544 12,569 7.8 7.8 - 25,849 24,189 6.9 6.9 -
International 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7)
Worldwide 23,743	$ 22,447 5.8 % 4.6 1.2 45,636	$ 43,830 4.1 % 4.4 (0.3)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER SIX MONTHS
Percent Change

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 2024 Total Operations Currency 2025 2024 Total Operations Currency
Sales to customers by
geographic area
U.S. 13,544	$ 12,569 7.8 % 7.8 - 25,849	$ 24,189 6.9 % 6.9 -
Europe 5,387 5,214 3.3 (1.9) 5.2 10,497 10,377 1.1 0.2 0.9
Western Hemisphere excluding U.S. 1,206 1,212 (0.5) 6.2 (6.7) 2,373 2,406 (1.3) 7.7 (9.0)
Asia-Pacific, Africa 3,606 3,452 4.4 2.4 2.0 6,917 6,858 0.9 0.9 0.0
International 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7)
Worldwide 23,743	$ 22,447 5.8 % 4.6 1.2 45,636	$ 43,830 4.1 % 4.4 (0.3)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER SIX MONTHS
Percent Change

-- 3 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
ONCOLOGY
US 3,385	$ 2,636 28.4% 28.4% - 6,398	$ 5,019 27.5% 27.5% -
Intl 2,928 2,455 19.3% 15.7% 3.6% 5,592 4,885 14.5% 15.1% -0.6%
WW 6,312 5,090 24.0% 22.3% 1.7% 11,990 9,904 21.1% 21.3% -0.2%
CARVYKTI
US 358 167 * * - 676 307 * * -
Intl 81 20 * * * 132 36 * * *
WW 439 186 * * * 808 343 * * *
DARZALEX
US 2,017 1,641 23.0% 23.0% - 3,846 3,105 23.9% 23.9% -
Intl 1,521 1,237 23.0% 19.6% 3.4% 2,930 2,465 18.9% 19.7% -0.8%
WW 3,539 2,878 23.0% 21.5% 1.5% 6,776 5,570 21.7% 22.0% -0.3%
ERLEADA
US 378 318 18.6% 18.6% - 670 603 11.0% 11.0% -
Intl 530 418 27.0% 22.8% 4.2% 1,009 822 22.9% 23.0% -0.1%
WW 908 736 23.4% 21.0% 2.4% 1,679 1,425 17.8% 17.9% -0.1%
IMBRUVICA
US 239 246 -2.7% -2.7% - 474 511 -7.3% -7.3% -
Intl 496 525 -5.4% -8.4% 3.0% 970 1,043 -6.9% -6.3% -0.6%
WW 735 770 -4.5% -6.6% 2.1% 1,444 1,554 -7.0% -6.6% -0.4%
RYBREVANT / LAZCLUZE (3)
US 139 52 * * - 252 88 * * -
Intl 41 17 * * * 69 28 * * *
WW 179 69 * * * 320 116 * * *
TALVEY
US 82 59 38.0% 38.0% - 150 109 36.7% 36.7% -
Intl 24 9 * * * 42 17 * * *
WW 106 69 55.0% 54.3% 0.7% 192 127 52.0% 52.4% -0.4%
TECVAYLI
US 114 104 8.2% 8.2% - 219 205 6.6% 6.6% -
Intl 52 30 74.8% 72.0% 2.8% 98 63 56.0% 58.4% -2.4%
WW 166 135 23.1% 22.4% 0.7% 317 268 18.2% 18.7% -0.5%
ZYTIGA / abiraterone acetate
US 6 11 -38.9% -38.9% - 13 20 -31.9% -31.9% -
Intl 139 154 -9.8% -13.3% 3.5% 257 326 -21.1% -21.3% 0.2%
WW 145 165 -11.6% -14.9% 3.3% 270 346 -21.7% -21.9% 0.2%
OTHER ONCOLOGY
US 50 37 36.9% 36.9% - 97 70 39.8% 39.8% -
Intl 42 45 -8.7% -12.3% 3.6% 84 86 -2.5% -1.8% -0.7%
WW 93 83 11.7% 9.7% 2.0% 182 156 16.4% 16.8% -0.4%
See footnotes at end of schedule
% Change	% Change

-- 4 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
IMMUNOLOGY
US 2,505	$ 2,978 -15.9% -15.9% - 4,701	$ 5,431 -13.4% -13.4% -
Intl 1,489 1,744 -14.6% -16.2% 1.6% 2,999 3,538 -15.2% -13.8% -1.4%
WW 3,993 4,722 -15.4% -16.0% 0.6% 7,700 8,969 -14.1% -13.6% -0.5%
REMICADE
US 283 231 22.5% 22.5% - 597 497 20.1% 20.1% -
US Exports (4) 34 35 -2.6% -2.6% - 44 62 -28.7% -28.7% -
Intl 138 127 8.6% 8.8% -0.2% 281 268 4.8% 7.7% -2.9%
WW 455 393 15.9% 15.9% 0.0% 922 827 11.5% 12.4% -0.9%
SIMPONI / SIMPONI ARIA
US 305 267 14.0% 14.0% - 597 521 14.4% 14.4% -
Intl 387 270 43.1% 40.8% 2.3% 753 569 32.2% 35.0% -2.8%
WW 690 537 28.6% 27.5% 1.1% 1,349 1,091 23.7% 25.1% -1.4%
STELARA
US 1,078 1,855 -41.9% -41.9% - 2,059 3,251 -36.7% -36.7% -
Intl 575 1,030 -44.2% -45.6% 1.4% 1,219 2,085 -41.5% -40.6% -0.9%
WW 1,653 2,885 -42.7% -43.2% 0.5% 3,278 5,336 -38.6% -38.2% -0.4%
TREMFYA
US 796 589 35.2% 35.2% - 1,395 1,098 27.1% 27.1% -
Intl 391 317 23.2% 20.5% 2.7% 747 616 21.2% 22.4% -1.2%
WW 1,186 906 31.0% 30.1% 0.9% 2,142 1,714 25.0% 25.4% -0.4%
OTHER IMMUNOLOGY
US 8 2 * * - 9 2 * * -
Intl 0 0 - - - 0 0 - - -
WW 8 2 * * - 9 2 * * -
NEUROSCIENCE
US 1,377 1,102 24.9% 24.9% - 2,345 2,156 8.7% 8.7% -
Intl 674 679 -0.8% -2.6% 1.8% 1,353 1,428 -5.2% -4.1% -1.1%
WW 2,051 1,782 15.1% 14.4% 0.7% 3,698 3,585 3.2% 3.6% -0.4%
CAPLYTA (5)
US 211 - * * - 211 - * * -
Intl - - - - - - - - - -
WW 211 - * * - 211 - * * -
CONCERTA / Methylphenidate
US 24 34 -27.7% -27.7% - 62 75 -16.6% -16.6% -
Intl 139 129 7.5% 7.0% 0.5% 249 265 -6.0% -4.4% -1.6%
WW 164 163 0.2% -0.2% 0.4% 312 340 -8.3% -7.1% -1.2%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 732 784 -6.7% -6.7% - 1,357 1,549 -12.4% -12.4% -
Intl 260 269 -3.5% -5.1% 1.6% 537 561 -4.2% -3.1% -1.1%
WW 992 1,054 -5.9% -6.3% 0.4% 1,895 2,110 -10.2% -9.9% -0.3%
SPRAVATO
US 366 226 61.1% 61.1% - 642 417 53.7% 53.7% -
Intl 50 44 12.8% 11.0% 1.8% 93 78 18.1% 20.1% -2.0%
WW 414 271 53.3% 53.0% 0.3% 734 496 48.1% 48.4% -0.3%
OTHER NEUROSCIENCE
US 45 57 -23.5% -23.5% - 73 115 -37.0% -37.0% -
Intl 226 237 -4.7% -7.6% 2.9% 474 524 -9.5% -8.8% -0.7%
WW 270 294 -8.4% -10.7% 2.3% 547 639 -14.4% -13.9% -0.5%
See footnotes at end of schedule
% Change	% Change

-- 5 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 799	$ 743 7.6% 7.6% - 1,543	$ 1,509 2.3% 2.3% -
Intl 314 296 5.8% 2.8% 3.0% 595 579 2.6% 3.0% -0.4%
WW 1,113 1,039 7.1% 6.2% 0.9% 2,138 2,088 2.4% 2.5% -0.1%
OPSUMIT / OPSYNVI
US 403 376 6.9% 6.9% - 766 732 4.6% 4.6% -
Intl 180 171 5.4% 2.1% 3.3% 339 340 -0.3% -0.2% -0.1%
WW 582 548 6.4% 5.4% 1.0% 1,104 1,072 3.0% 3.1% -0.1%
UPTRAVI
US 382 349 9.4% 9.4% - 747 741 0.8% 0.8% -
Intl 94 76 22.4% 19.8% 2.6% 180 152 17.9% 18.7% -0.8%
WW 476 426 11.7% 11.3% 0.4% 927 894 3.7% 3.8% -0.1%
OTHER PULMONARY HYPERTENSION
US 16 17 -12.4% -12.4% - 31 35 -12.6% -12.6% -
Intl 40 49 -18.5% -21.3% 2.8% 77 88 -12.4% -12.1% -0.3%
WW 55 67 -16.9% -19.0% 2.1% 107 123 -12.5% -12.3% -0.2%
INFECTIOUS DISEASES
US 320 334 -4.3% -4.3% - 635 658 -3.6% -3.6% -
Intl 484 631 -23.4% -26.8% 3.4% 971 1,128 -13.9% -14.1% 0.2%
WW 803 965 -16.8% -19.0% 2.2% 1,605 1,786 -10.1% -10.2% 0.1%
EDURANT / rilpivirine
US 6 8 -25.4% -25.4% - 14 16 -13.6% -13.6% -
Intl 354 288 23.0% 16.7% 6.3% 704 603 16.7% 15.6% 1.1%
WW 360 297 21.6% 15.5% 6.1% 718 620 15.9% 14.9% 1.0%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 312 321 -3.0% -3.0% - 617 635 -2.9% -2.9% -
Intl 85 117 -27.0% -29.4% 2.4% 183 221 -17.2% -15.8% -1.4%
WW 396 438 -9.4% -10.0% 0.6% 799 856 -6.6% -6.3% -0.3%
OTHER INFECTIOUS DISEASES
US 2 5 -51.8% -51.8% - 4 7 -37.4% -37.4% -
Intl 45 227 -80.5% -80.6% 0.1% 84 304 -72.5% -72.1% -0.4%
WW 47 233 -79.8% -79.9% 0.1% 88 311 -71.7% -71.3% -0.4%
CARDIOVASCULAR / METABOLISM / OTHER
US 776 717 8.2% 8.2% - 1,631 1,348 21.0% 21.0% -
Intl 154 176 -12.3% -13.2% 0.9% 312 373 -16.2% -14.3% -1.9%
WW 930 892 4.2% 4.0% 0.2% 1,943 1,721 12.9% 13.3% -0.4%
XARELTO
US 621 587 5.6% 5.6% - 1,311 1,105 18.6% 18.6% -
Intl - - - - - - - - - -
WW 621 587 5.6% 5.6% - 1,311 1,105 18.6% 18.6% -
OTHER
US 155 129 20.0% 20.0% - 320 243 31.6% 31.6% -
Intl 154 176 -12.3% -13.2% 0.9% 312 373 -16.2% -14.3% -1.9%
WW 309 305 1.4% 0.9% 0.5% 632 616 2.7% 3.9% -1.2%
TOTAL INNOVATIVE MEDICINE
US 9,161 8,510 7.6% 7.6% - 17,253 16,122 7.0% 7.0% -
Intl 6,041 5,980 1.0% -1.6% 2.6% 11,822 11,930 -0.9% -0.1% -0.8%
WW 15,202	$ 14,490 4.9% 3.8% 1.1% 29,075	$ 28,052 3.6% 4.0% -0.4%
See footnotes at end of schedule
% Change	% Change

-- 6 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,364	$ 1,119 21.9% 21.9% - 2,625	$ 2,144 22.4% 22.4% -
Intl 948 753 25.9% 22.9% 3.0% 1,790 1,534 16.7% 16.7% 0.0%
WW 2,313 1,873 23.5% 22.3% 1.2% 4,416 3,679 20.0% 20.0% 0.0%
ELECTROPHYSIOLOGY
US 741 705 5.1% 5.1% - 1,425 1,397 2.0% 2.0% -
Intl 728 618 17.8% 15.2% 2.6% 1,366 1,270 7.6% 7.8% -0.2%
WW 1,468 1,323 11.0% 9.8% 1.2% 2,791 2,667 4.7% 4.7% 0.0%
ABIOMED
US 360 309 16.6% 16.6% - 699 612 14.2% 14.2% -
Intl 89 72 25.0% 18.4% 6.6% 170 139 22.4% 20.9% 1.5%
WW 448 379 18.2% 16.9% 1.3% 868 750 15.7% 15.5% 0.2%
SHOCKWAVE (6)
US 233 77 * * - 439 77 * * -
Intl 58 0 * * * 110 0 * * *
WW 292 77 * * * 550 77 * * -
OTHER CARDIOVASCULAR
US 31 29 5.4% 5.4% - 63 59 6.3% 6.3% -
Intl 72 64 13.4% 11.6% 1.8% 144 126 14.2% 14.5% -0.3%
WW 104 93 10.8% 9.7% 1.1% 207 185 11.7% 11.8% -0.1%
ORTHOPAEDICS
US 1,420 1,422 -0.2% -0.2% - 2,804 2,870 -2.3% -2.3% -
Intl 885 890 -0.5% -4.0% 3.5% 1,742 1,782 -2.2% -2.4% 0.2%
WW 2,305 2,312 -0.3% -1.6% 1.3% 4,546 4,652 -2.3% -2.3% 0.0%
HIPS
US 271 265 2.1% 2.1% - 534 535 -0.2% -0.2% -
Intl 150 152 -1.0% -4.3% 3.3% 296 304 -2.5% -2.6% 0.1%
WW 421 417 1.0% -0.2% 1.2% 830 839 -1.1% -1.1% 0.0%
KNEES
US 226 230 -1.9% -1.9% - 457 472 -3.1% -3.1% -
Intl 164 163 0.0% -2.9% 2.9% 322 323 -0.5% -0.4% -0.1%
WW 389 394 -1.1% -2.3% 1.2% 778 795 -2.0% -2.0% 0.0%
TRAUMA
US 501 498 0.7% 0.7% - 1,003 1,002 0.1% 0.1% -
Intl 267 260 2.2% -1.5% 3.7% 537 521 2.9% 2.8% 0.1%
WW 768 759 1.2% -0.1% 1.3% 1,540 1,524 1.1% 1.0% 0.1%
SPINE, SPORTS & OTHER
US 422 430 -1.7% -1.7% - 810 862 -6.0% -6.0% -
Intl 305 314 -2.7% -6.4% 3.7% 588 634 -7.2% -7.7% 0.5%
WW 727 743 -2.1% -3.7% 1.6% 1,398 1,495 -6.5% -6.7% 0.2%
See footnotes at end of schedule
% Change	% Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
SURGERY
US 1,043	$ 995 4.8% 4.8% - 2,045	$ 1,982 3.2% 3.2% -
Intl 1,512 1,493 1.3% -0.2% 1.5% 2,906 2,922 -0.5% 0.3% -0.8%
WW 2,555 2,488 2.7% 1.8% 0.9% 4,951 4,904 1.0% 1.5% -0.5%
ADVANCED
US 477 466 2.2% 2.2% - 934 912 2.4% 2.4% -
Intl 687 675 1.9% 0.2% 1.7% 1,303 1,316 -1.0% -0.4% -0.6%
WW 1,164 1,141 2.0% 1.0% 1.0% 2,237 2,228 0.4% 0.8% -0.4%
GENERAL
US 567 528 7.2% 7.2% - 1,111 1,070 3.8% 3.8% -
Intl 825 818 0.9% -0.6% 1.5% 1,603 1,606 -0.1% 0.8% -0.9%
WW 1,391 1,346 3.3% 2.5% 0.8% 2,714 2,676 1.4% 2.0% -0.6%
VISION
US 557 523 6.5% 6.5% - 1,123 1,070 4.9% 4.9% -
Intl 813 763 6.5% 3.4% 3.1% 1,526 1,473 3.6% 3.7% -0.1%
WW 1,369 1,285 6.5% 4.6% 1.9% 2,648 2,543 4.1% 4.2% -0.1%
CONTACT LENSES / OTHER
US 429 409 4.8% 4.8% - 881 847 3.9% 3.9% -
Intl 536 509 5.4% 1.4% 4.0% 1,003 981 2.3% 1.9% 0.4%
WW 965 918 5.1% 2.9% 2.2% 1,884 1,828 3.1% 2.8% 0.3%
SURGICAL
US 128 113 12.6% 12.6% - 242 223 8.5% 8.5% -
Intl 277 254 8.8% 7.3% 1.5% 523 492 6.2% 7.2% -1.0%
WW 403 367 9.9% 8.9% 1.0% 764 715 6.9% 7.6% -0.7%
TOTAL MEDTECH
US 4,383 4,059 8.0% 8.0% - 8,596 8,067 6.6% 6.6% -
Intl 4,158 3,898 6.7% 4.1% 2.6% 7,965 7,711 3.3% 3.6% -0.3%
WW 8,541	$ 7,957 7.3% 6.1% 1.2% 16,561	$ 15,778 5.0% 5.1% -0.1%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
(6) Acquired on May 31, 2024
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change	% Change

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 23,743	$ 100.0 22,447	$ 100.0 5.8
Cost of products sold 7,628 32.1 6,869 30.6 11.0
Gross Profit 16,115 67.9 15,578 69.4 3.4
Selling, marketing and administrative expenses 5,889 24.8 5,681 25.3 3.7
Research and development expense 3,516 14.8 3,440 15.3 2.2
In-process research and development impairments - - 194 0.9
Interest (income) expense, net 48 0.2 (125) (0.6)
Other (income) expense, net 107 0.5 653 2.9
Restructuring 64 0.3 (13) 0.0
Earnings before provision for taxes on income 6,491 27.3 5,748 25.6 12.9
Provision for taxes on income 954 4.0 1,062 4.7 (10.2)
Net earnings 5,537	$ 23.3 4,686	$ 20.9 18.2
Net earnings per share (Diluted) 2.29	$ 1.93	$ 18.7
Average shares outstanding (Diluted) 2,419.1 2,422.0
Effective tax rate 14.7 % 18.5 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 8,188	$ 34.5 8,404	$ 37.4 (2.6)
Net earnings 6,699	$ 28.2 6,840	$ 30.5 (2.1)
Net earnings per share (Diluted) 2.77	$ 2.82	$ (1.8)
Effective tax rate 18.2 % 18.6 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2025 2024

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 45,636	$ 100.0 43,830	$ 100.0 4.1
Cost of products sold 14,985 32.8 13,380 30.5 12.0
Gross Profit 30,651 67.2 30,450 69.5 0.7
Selling, marketing and administrative expenses 11,001 24.1 10,938 25.0 0.6
Research and development expense 6,741 14.8 6,982 16.0 (3.5)
In-process research and development impairments - - 194 0.4
Interest (income) expense, net (80) (0.2) (334) (0.8)
Other (income) expense, net (7,214) (15.8) 3,057 7.0
Restructuring 81 0.2 151 0.3
Earnings before provision for taxes on income 20,122 44.1 9,462 21.6 112.7
Provision for taxes on income 3,586 7.9 1,521 3.5 135.8
Net earnings 16,536	$ 36.2 7,941	$ 18.1 108.2
Net earnings per share (Diluted) 6.82	$ 3.27	$ 108.6
Average shares outstanding (Diluted) 2,423.3 2,428.5
Effective tax rate 17.8 % 16.1 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 16,199	$ 35.5 16,281	$ 37.1 (0.5)
Net earnings 13,405	$ 29.4 13,420	$ 30.6 (0.1)
Net earnings per share (Diluted) 5.53	$ 5.53	$ 0.0
Effective tax rate 17.2 % 17.6 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2025 2024

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 4.9% 7.3% 5.8%
U.S. 7.6% 8.0% 7.8%
International 1.0% 6.7% 3.2%
WW Currency 1.1 1.2 1.2
U.S. - - -
International 2.6 2.6 2.6
WW Operational 3.8% 6.1% 4.6%
U.S. 7.6% 8.0% 7.8%
International (1.6)% 4.1% 0.6%
Shockwave (2.2) (0.8)
U.S. (3.5) (1.1)
International (0.9) (0.3)
Caplyta (1.4) (0.9)
U.S. (2.4) (1.7)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.2 0.1
U.S. 0.0 0.2 0.0
International 0.0 0.2 0.1
WW Adjusted Operational Ex A&D 2.4% 4.1% 3.0%
U.S. 5.2% 4.7% 5.0%
International (1.6)% 3.4% 0.4%
Adjusted Operational Sales Growth
SECOND QUARTER 2025 ACTUAL vs. 2024 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 3.6% 5.0% 4.1%
U.S. 7.0% 6.6% 6.9%
International (0.9)% 3.3% 0.7%
WW Currency (0.4) (0.1) (0.3)
U.S. - - -
International (0.8) (0.3) (0.7)
WW Operational 4.0% 5.1% 4.4%
U.S. 7.0% 6.6% 6.9%
International (0.1)% 3.6% 1.4%
Shockwave (2.7) (1.0)
U.S. (4.3) (1.5)
International (1.1) (0.5)
Caplyta (0.8) (0.5)
U.S. (1.3) (0.9)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.1 0.3 0.2
U.S. 0.0 0.5 0.2
International 0.2 0.2 0.2
WW Adjusted Operational Ex A&D 3.3% 2.7% 3.1%
U.S. 5.7% 2.8% 4.7%
International 0.1% 2.7% 1.1%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2025 ACTUAL vs. 2024 ACTUAL
Segments

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2025 2024 2025 2024
Net Earnings, after tax- as reported $5,537 $4,686 $16,536 $7,941
Pre-tax Adjustments
Litigation related 57 352 (6,909) 3,078
Intangible Asset Amortization expense 1,267 1,106 2,387 2,184
COVID-19 Vaccine related costs - 64 - 73
Restructuring related 1 79 (11) 134 160
Medical Device Regulation - 68 - 119
Acquisition, integration and divestiture related 246 452 378 600
(Gains)/losses on securities 21 431 60 411
IPR&D impairments - 194 - 194
Other 27 - 27 -
Tax Adjustments
Tax impact on special item adjustments 2 (321) (437) 994 (1,293)
Tax legislation and other tax related (214) (65) (202) (47)
Adjusted Net Earnings , after tax $6,699 $6,840 $13,405 $13,420
Average shares outstanding (Diluted) 2,419.1 2,422.0 2,423.3 2,428.5
Adjusted net earnings per share (Diluted) $2.77 $2.82 $5.53 $5.53
Operational adjusted net earnings per share (Diluted) $2.71 $5.52
Notes:
1
2
Second Quarter Six Months Ended
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest
benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory
syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) included asset
divestments and the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network
arrangements. The restructuring expenses of $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) and $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes
costs related to market and product exits.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize
select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 13 of 17 --

Innovative Medicine
Second Quarter June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter June
29, 2025
Non-GAAP
Cost of products sold 3,978	$ (785) (13) 3,180
Selling, marketing and admin expenses 2,789 2,789
Research and development expense 2,869 2,869
Other segment items 14 69 (207) 8 (13) (129)
Adjusted Income Before Tax by Segment 5,552 785 (69) - 220 (8) - 13 6,493
MedTech
Second Quarter June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter June
29, 2025
Non-GAAP
Cost of products sold 3,638	$ (482) (15) 1 3,142
Selling, marketing and admin expenses 2,862 2,862
Research and development expense 647 43 690
Other segment items 190 (83) (64) (53) (29) (14) (53)
Adjusted Income Before Tax by Segment 1,204 482 83 79 9 29 - 14 1,900
Expenses not allocated to segments
Second Quarter June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter June
29, 2025
Non-GAAP
Cost of products sold 12	$ 12
Selling, marketing and admin expenses 238 238
Research and development expense - -
Other segment items 15 (43) (17) (45)
Adjusted Income Before Tax by Segment (265) - 43 - 17 - - - (205)
Johnson & Johnson Consolidated
Second Quarter June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter June
29, 2025
Non-GAAP
Cost of products sold 7,628	$ (1,267) (15) (12) 6,334
Selling, marketing and admin expenses 5,889 5,889
Research and development expense 3,516 43 3,559
Other (Income) / Expense 107 (57) (277) (21) (27) (275)
In-process research and development impairments - -
Interest (Income)/Expense 48 48
Restructuring 64 (64) -
Adjusted Income Before Tax 6,491 1,267 57 79 246 21 - 27 8,188
Provision for taxes on income 954 222 9 13 72 5 214 - 1,489
Net Earnings 5,537 1,045 48 66 174 16 (214) 27 6,699
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 14 of 17 --

Innovative Medicine
Second Quarter
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Second Quarter
June 30, 2024
Non-GAAP
Cost of products sold 3,603	$ (694) (4) 2,905
Selling, marketing and admin expenses 2,665 2,665
Research and development expense 2,722 (10) 2,712
Other segment items 41 (43) (194) 63 (1) (70) (50) (254)
Adjusted Income Before Tax by Segment 5,459 694 43 194 (63) 1 70 - 64 - 6,462
MedTech
Second Quarter
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Second Quarter
June 30, 2024
Non-GAAP
Cost of products sold 3,248	$ (412) (2) (50) (30) 2,754
Selling, marketing and admin expenses 2,671 (5) 2,666
Research and development expense 718 (15) (33) 670
Other segment items 231 4 (50) (344) (22) (181)
Adjusted Income Before Tax by Segment 1,089 412 (4) - 52 409 22 68 - - 2,048
Expenses not allocated to segments
Second Quarter
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Second Quarter
June 30, 2024
Non-GAAP
Cost of products sold 18	$ 18
Selling, marketing and admin expenses 345 345
Research and development expense - -
Other segment items 437 (313) (42) (339) (257)
Adjusted Income Before Tax by Segment (800) - 313 - - 42 339 - - - (106)
Johnson & Johnson Consolidated
Second Quarter
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Second Quarter
June 30, 2024
Non-GAAP
Cost of products sold 6,869	$ (1,106) (2) (50) (30) (4) 5,677
Selling, marketing and admin expenses 5,681 (5) 5,676
Research and development expense 3,440 (15) (33) (10) 3,382
Other (Income) / Expense 653 (352) (387) (431) (50) (567)
In-process research and development impairments 194 (194) -
Interest (Income)/Expense (125) (125)
Restructuring (13) 13 -
Adjusted Income Before Tax 5,748 1,106 352 194 (11) 452 431 68 64 - 8,404
Provision for taxes on income 1,062 156 70 43 (6) 125 21 14 14 65 1,564
Net Earnings 4,686 950 282 151 (5) 327 410 54 50 (65) 6,840
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 15 of 17 --

Year to Date
Innovative Medicine
Six Months
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months
June 29, 2025
Non-GAAP
Cost of products sold 7,998	$ (1,434) (13) 6,551
Selling, marketing and admin expenses 5,050 5,050
Research and development expense 5,417 5,417
Other segment items (152) 69 (227) (10) (13) (333)
Adjusted Income Before Tax by Segment 10,762 1,434 (69) - 240 10 - 13 12,390
MedTech
Six Months
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months
June 29, 2025
Non-GAAP
Cost of products sold 6,964	$ (953) (23) (51) 5,937
Selling, marketing and admin expenses 5,518 5,518
Research and development expense 1,324 37 1,361
Other segment items 130 (83) (111) (107) (50) (14) (235)
Adjusted Income Before Tax by Segment 2,625 953 83 134 121 50 - 14 3,980
Expenses not allocated to segments
Six Months
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months
June 29, 2025
Non-GAAP
Cost of products sold 23	$ 23
Selling, marketing and admin expenses 433 433
Research and development expense - -
Other segment items (7,191) 6,923 (17) (285)
Adjusted Income Before Tax by Segment 6,735 - (6,923) - 17 - - - (171)
Johnson & Johnson Consolidated
Six Months
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months
June 29, 2025
Non-GAAP
Cost of products sold 14,985	$ (2,387) (23) (64) 12,511
Selling, marketing and admin expenses 11,001 11,001
Research and development expense 6,741 37 6,778
Other (Income) / Expense (7,214) 6,909 (30) (351) (60) (27) (773)
In-process research and development impairments - -
Interest (Income)/Expense (80) (80)
Restructuring 81 (81) -
Adjusted Income Before Tax 20,122 2,387 (6,909) 134 378 60 - 27 16,199
Provision for taxes on income 3,586 410 (1,544) 24 102 14 202 2,794
Net Earnings 16,536 1,977 (5,365) 110 276 46 (202) 27 13,405
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 16 of 17 --

Innovative Medicine
Six Months
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Six Months
June 30, 2024
Non-GAAP
Cost of products sold 6,973	$ (1,392) (6) 5,575
Selling, marketing and admin expenses 5,103 5,103
Research and development expense 5,618 (17) 5,601
Other segment items (70) (43) (194) (81) (48) (15) (50) (501)
Adjusted Income Before Tax by Segment 10,428 1,392 43 194 81 48 15 - 73 - 12,274
MedTech
Six Months
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Six Months
June 30, 2024
Non-GAAP
Cost of products sold 6,368	$ (792) (9) (50) (50) 5,467
Selling, marketing and admin expenses 5,253 (9) 5,244
Research and development expense 1,364 (33) (60) 1,271
Other segment items 184 4 (70) (387) (44) (313)
Adjusted Income Before Tax by Segment 2,609 792 (4) - 79 470 44 119 - - 4,109
Expenses not allocated to segments
Six Months
June 30, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Six Months
June 30, 2024
Non-GAAP
Cost of products sold 39	$ 39
Selling, marketing and admin expenses 582 582
Research and development expense - -
Other segment items 2,954 (3,039) (82) (352) (519)
Adjusted Income Before Tax by Segment (3,575) - 3,039 - - 82 352 - - - (102)
Johnson & Johnson Consolidated
Six Months
June 30, 2024
GAAP
Intangible
asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Six Months
June 30, 2024
Non-GAAP
Cost of products sold 13,380	$ (2,184) (9) (50) (50) (6) 11,081
Selling, marketing and admin expenses 10,938 (9) 10,929
Research and development expense 6,982 (33) (60) (17) 6,872
Other (Income) / Expense 3,057 (3,078) (517) (411) (50) (999)
In-process research and development impairments 194 (194) -
Interest (Income)/Expense (334) (334)
Restructuring 151 (151) -
Adjusted Income Before Tax 9,462 2,184 3,078 194 160 600 411 119 73 - 16,281
Provision for taxes on income 1,521 304 697 43 33 163 14 23 16 47 2,861
Net Earnings 7,941 1,880 2,381 151 127 437 397 96 57 (47) 13,420
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 17 of 17 --